Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: First Line Treatment of Familiar Lymphohistiocytosis by Alemtuzumab (CAMPATH®)
Brief Summary: The purpose of this project is to study the number of surviving patients until hematopoietic stem cell transplantation (HSCT) after first line treatment of hemophagocytic lymphohistiocytosis (HLH) by Alemtuzumab